---
title: "Sagimet Biosciences Gets FDA Clearance For Phase 3 Acne Study"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295789901.md"
description: "Sagimet Biosciences (SGMT) received FDA clearance for a Phase 3 study of denifanstat for moderate to severe acne. The trial, starting in late 2026, will enroll ~800 US patients aged 12+, assessing treatment success and lesion count changes over 12 weeks. Shares rose ~1% pre-market."
datetime: "2026-08-13T11:26:49.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295789901.md)
  - [en](https://longbridge.com/en/news/295789901.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295789901.md)
generator: "portal-rs"
---

# Sagimet Biosciences Gets FDA Clearance For Phase 3 Acne Study

Add  as your preferred news source on Google

 Add Now

Sagimet Biosciences Inc. (SGMT), a clinical-stage biopharmaceutical company, on Thursday said it has received clearance from the U.S. Food and Drug Administration (FDA) for a Phase 3 study of denifanstat in moderate to severe acne.

The study is expected to begin in the second half of 2026 and enroll approximately 800 U.S. patients aged 12 years and older, including about 450 adolescents aged 12 to 17. Patients will be randomized to receive denifanstat 50 mg or placebo once daily for 12 weeks.

The trial will have three co-primary endpoints assessed at week 12, including treatment success based on a global assessment score and changes in inflammatory and non-inflammatory skin lesion counts from baseline.

Sagimet shares were up about 1% in pre-market trading after closing at $9.39 on Wednesday. 

For comments and feedback contact: editorial@rttnews.com

Business News

### Related Stocks

- [SGMT.US](https://longbridge.com/en/quote/SGMT.US.md)

## Related News & Research

- [Sagimet Biosciences Eyes U.S. Phase III Acne Study After Positive China Data](https://longbridge.com/en/news/296073364.md)
- [Sagimet wins FDA IND clearance for Phase 3 denifanstat acne trial](https://longbridge.com/en/news/295786871.md)
- [Sagimet Biosciences grants 260,700 inducement stock options to new hires](https://longbridge.com/en/news/296143081.md)
- [Sagimet to advance denifanstat Phase 3 in US; $104.5M cash, $175M offering funds operations through 2028](https://longbridge.com/en/news/293324312.md)
- [Yalla’s Bet On New Mid-And Hardcore Gaming Titles Pays Off](https://longbridge.com/en/news/296504966.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**